Plant ID: NPO24043
Plant Latin Name: Tylophora asthmatica
Taxonomy Genus: Tylophora
Taxonomy Family: Apocynaceae
NCBI TaxonomyDB:
1266040
Plant-of-the-World-Online:
n.a.
India; Philippines; China
TSHR; | |
PKM; | |
PTGS1; PTGS2; | |
JUN; | |
LMNA; NPC1; THPO; RAB9A; | |
SMN1;SMN2; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
Methyl-lysine/arginine binding protein | SMN1;SMN2 | Survival motor neuron protein | Q16637 | CHEMBL1293232 |
Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
Oxidoreductase | PTGS2 | Cyclooxygenase-2 | P35354 | CHEMBL230 |
Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
Transcription Factor | JUN | Proto-oncogene c-JUN | P05412 | CHEMBL4977 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | NPC1 | Niemann-Pick C1 protein | O15118 | CHEMBL1293277 |
Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Unclassified | RAB9A | Ras-related protein Rab-9A | P51151 | CHEMBL1293294 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0020037; heme binding | 5.176E-12 | 5.635E-08 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 6.572E-11 | 2.862E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 2.338E-10 | 5.657E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 1.863E-09 | 3.120E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 2.753E-09 | 4.282E-06 | CYP1A1, CYP1A2, CYP1B1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 9.312E-09 | 1.267E-05 | CYP1A2, CYP2C19, CYP3A4 |
BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 1.021E-07 | 9.668E-05 | CYP1A2, CYP2C19, CYP3A4 |
MF | GO:0005488; binding | GO:0005506; iron ion binding | 1.486E-07 | 1.294E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4 |
CC | GO:0016020; membrane | GO:0005789; endoplasmic reticulum membrane | 2.370E-07 | 1.912E-04 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, PTGS1, PTGS2, RAB9A |
MF | GO:0003824; catalytic activity | GO:0004666; prostaglandin-endoperoxide synthase activity | 6.433E-07 | 4.584E-04 | PTGS1, PTGS2 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 8.175E-07 | 5.563E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0003824; catalytic activity | GO:0070576; vitamin D 24-hydroxylase activity | 1.929E-06 | 1.135E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 3.856E-06 | 1.908E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 3.856E-06 | 1.908E-03 | CYP1A2, CYP3A4 |
BP | GO:0032502; developmental process | GO:0048856; anatomical structure development | 5.217E-06 | 2.469E-03 | CYP1A1, CYP1A2, CYP1B1, JUN, LMNA, PKM, PTGS2, SMN1, SMN2, THPO, TSHR |
MF | GO:0003824; catalytic activity | GO:0101020; estrogen 16-alpha-hydroxylase activity | 6.423E-06 | 2.797E-03 | CYP1A1, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0002933; lipid hydroxylation | 9.631E-06 | 3.957E-03 | CYP1A1, CYP3A4 |
CC | GO:0016020; membrane | GO:0031090; organelle membrane | 1.055E-05 | 4.179E-03 | CYP1A1, CYP1A2, CYP1B1, CYP2C19, CYP3A4, LMNA, NPC1, PTGS1, PTGS2, RAB9A |
BP | GO:0050896; response to stimulus | GO:0046686; response to cadmium ion | 1.258E-05 | 4.893E-03 | CYP1A2, JUN, NPC1 |
BP | GO:0008152; metabolic process | GO:0009820; alkaloid metabolic process | 1.348E-05 | 5.148E-03 | CYP1A2, CYP3A4 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 1.796E-05 | 6.518E-03 | CYP1A1, CYP1A2 |
CC | GO:0043226; organelle | GO:0097504; Gemini of coiled bodies | 4.225E-05 | 1.353E-02 | SMN1, SMN2 |
CC | GO:0032991; macromolecular complex | GO:0032797; SMN complex | 4.991E-05 | 1.489E-02 | SMN1, SMN2 |
CC | GO:0044464; cell part | GO:0034719; SMN-Sm protein complex | 9.766E-05 | 2.444E-02 | SMN1, SMN2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 3.056E-11 | 2.353E-09 | CYP1A2, CYP1A1, CYP1B1, CYP3A4, CYP2C19, PTGS2 |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.129E-07 | 4.346E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 2.875E-07 | 7.380E-06 | CYP1A2, CYP1A1, CYP1B1, CYP3A4 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 4.076E-06 | 6.277E-05 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 8.047E-06 | 1.033E-04 | CYP1A1, CYP1B1, PTGS2 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 1.516E-06 | 2.917E-05 | CYP1A2, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa04923 | Regulation of lipolysis in adipocytes | 1.135E-05 | 1.248E-04 | PTGS2, TSHR, PTGS1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.544E-05 | 1.486E-04 | CYP2C19, PTGS2, PTGS1 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 2.398E-05 | 1.679E-04 | PKM, CYP1A2, CYP1A1, PTGS2, CYP2C19, CYP3A4, PTGS1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.780E-05 | 1.523E-04 | CYP1A2, CYP1A1, CYP3A4 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 2.131E-05 | 1.641E-04 | CYP1A2, CYP3A4, CYP2C19 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 9.078E-05 | 5.825E-04 | CYP2C19, PTGS2, PTGS1 |
09160 Human Diseases | 09167 Infectious diseases | hsa05140 | Leishmaniasis | 1.526E-03 | 9.036E-03 | JUN, PTGS2 |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
R00-R99: Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified | Chronic pain | R52.1-R52.2, G89 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Ankylosing spondylitis | M08.1, M45 | PTGS2; |
C00-D49: Neoplasms | Cancer | C00-C96 | PTGS2; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PTGS2; JUN; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTGS2; |
NA: NA | Rheumatold arthritis | NA | PTGS2; |
C00-D49: Neoplasms | Non-small cell lung cancer | C33-C34 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | PTGS2; |
E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | PTGS2; |
K00-K95: Diseases of the digestive system | Inflammatory bowel disease | K50, K51 | PTGS2; |
C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PTGS2; |
NA: NA | Joint and muscular pain | NA | PTGS2; |
S00-T88: Injury, poisoning and certain other consequences of external causes | Hyperthermia | T68 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Osteoarthritis | M15-M19, M47 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | PTGS2; |
C00-D49: Neoplasms | Pancreatic cancer | C25 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | PTGS2; |
K00-K95: Diseases of the digestive system | Colon polyps | K63.5 | PTGS2; |
N00-N99: Diseases of the genitourinary system | Dysmenorrhea | N94.4-N94.6 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Knee osteoarthritis | M15-M19, M47 | PTGS2; |
G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | PTGS2; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Moderate to severe rheumatoid arthritis | M05-M06 | PTGS2; |